Noelia J. M.
- Country
- Spain
- Department
- Oncología Médica
Research Overview
- Phase 1 Study of Subcutaneous Trastuzumab Deruxtecan in Patients with Advanced Solid Tumors
- Efficacy and Safety of Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib in ER+/HER2- Advanced Breast Cancer with ESR1 Mutation
- Phase 3 Randomized Study of Datopotamab Deruxtecan vs. Chemotherapy in HR-Positive, HER2-Negative Metastatic Breast Cancer Post-Chemotherapy
Data & Insights
Has run more than one trial at 138 of 320 partner sites.
Specializations
Breast Cancer and Gynecologic Oncology
Clinical activity includes hormone receptor-positive, HER2-negative, and HER2-positive breast cancer, along with triple-negative breast cancer, endometrial cancer, ovarian cancer, and cervical cancer. The oncology portfolio also extends to advanced and metastatic settings, including tumors with PIK3CA alterations and other biomarker-defined disease.
- Advanced breast cancer
- Triple-negative breast cancer
- Endometrial and ovarian malignancies
- Biomarker-selected solid tumors
Research interests in this area reflect a strong focus on targeted and immune-based treatment strategies for recurrent, unresectable, and metastatic disease.
Lung Cancer and Thoracic Malignancies
The investigator is involved in studies of non-small cell lung cancer, small cell lung cancer, and molecularly defined thoracic tumors, including EGFR, ALK, ROS1, RET, and KRAS G12C alterations. This area also includes locally advanced, metastatic, and brain-metastatic disease.
- Non-small cell lung cancer
- Small cell lung cancer
- Actionable genomic alterations
- Metastatic thoracic disease
Therapeutic interest extends to precision oncology approaches and treatment options for difficult-to-control thoracic tumors.
Hematologic Malignancies
Research involvement covers multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, lymphomas, and chronic lymphocytic leukemia. The portfolio also includes aggressive and relapsed/refractory blood cancers, as well as transplant-related hematologic settings.
- Multiple myeloma
- Acute myeloid leukemia
- Non-Hodgkin lymphoma
- Myelodysplastic syndromes
Clinical interests in this domain align with novel immunotherapy, cellular therapy, and targeted treatment options for hematologic disease.
Renal, Urologic, and Hepatobiliary Cancers
The investigator is active in renal cell carcinoma, urothelial carcinoma, bladder cancer, hepatocellular carcinoma, and biliary tract cancer. This includes advanced, metastatic, and unresectable disease, with attention to tumors defined by specific molecular features.
- Renal cell carcinoma
- Urothelial carcinoma
- Hepatocellular carcinoma
- Biliary tract cancer
Therapeutic focus in this area includes systemic treatment strategies for high-risk solid tumors and disease control in advanced cancer settings.
Autoimmune, Inflammatory, and Cardiometabolic Disease
Clinical research also spans systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, thyroid eye disease, psoriasis, and inflammatory bowel disease, together with cardiovascular disease, heart failure, and atherosclerotic disease. Additional interests include chronic kidney disease and metabolic dysfunction-associated steatotic liver disease.
- Autoimmune and inflammatory disorders
- Cardiovascular risk reduction
- Chronic kidney disease
- Metabolic liver disease
The therapeutic landscape includes immune modulation, organ-protective strategies, and management of chronic systemic disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.